Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Awards & Appointments for June 2018

Ann-Marie Lindstrom  |  Issue: June 2018  |  June 21, 2018

Lurie Prize Goes to Autoimmune Researcher

Zhijian “James” Chen, PhDZhijian “James” Chen, PhD, is this year’s recipient of the Lurie Prize in Biomedical Sciences for his 2012 discovery of the enzyme cyclic GMP-AMP synthase (cGAS). Dr. Chen received the prize at the Foundation for the National Institutes of Health Award Ceremony in May.

His work revealed the paradoxical role the cGAS enzyme can play within the immune system. After entering a cell’s cytoplasm, the enzyme binds to the DNA of a virus. It then creates a cyclic GMP-AMP molecule that tells the immune system to fight the virus and other pathogens with DNA that can cause such diseases as tuberculosis and malaria. “This important defense system activates T cells to kill tumors,” says Dr. Chen.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Alternately, if the cGAS enzyme attaches itself to a person’s DNA and becomes hyperactive, it can trigger autoimmune diseases, including rheumatoid arthritis and lupus. “There is more to understand about cGAS pathway’s role in autoimmune diseases from lupus to cancer,” Dr. Chen says. Simply put, “Activate the pathway to fight cancer; inhibit it to fight lupus and RA.”

Therapies to target the pathway could introduce treatments for, or prevention of, those diseases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He says recent discoveries have shown the role the pathway plays in age-related diseases, too. Further research could lead to treatments for such conditions as macular degeneration, myocardial infarction and other products of low-grade, chronic inflammation.

Zhijian ‘James’ Chen, PhD, is this year’s recipient of the Lurie Prize in Biomedical Sciences.

Dr. Chen previously appeared in this column when he received the Lupus Research Institute (LRI) 2014 Distinguished Innovator Award. He is the George L. MacGregor Distinguished Chair in Biomedical Science and professor of molecular biology at the University of Texas Southwestern Medical Center, and an investigator at the Howard Hughes Medical Institute.

1st Pharmacy Rheumatology Residency Begins

Jessica Farrell, PharmDJessica Farrell, PharmD, is an associate professor at Albany (N.Y.) College of Pharmacy and Health Sciences who also works as a clinical pharmacist for the Center for Rheumatology in Albany. This summer, she will add program director of the first PGY-2 (postgraduate year two) pharmacy rheumatology residency to her duties.

She is the driving force behind the postgraduate program she recognized a need for. “Although there is specialized training in areas like oncology, critical care, infectious disease and general family practice, there is no program in rheumatology,” Dr. Farrell says. “During the past five years, rheumatology has really blown up, especially regarding medications.”

Page: 1 2 3 | Single Page
Share: 

Filed under:Profiles Tagged with:Dr. Jessica FarrellDr. Timothy NiewoldDr. Zhijian James Chen

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    July 18, 2019

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    2018 ACR Awards of Distinction & ACR Masters

    November 19, 2018

    CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. You’ll also find the 2018 Masters list. In the next issue,…

    Rheumatologists on the Move, January 2016

    January 19, 2016

    2015 Mary Betty Stevens Young Investigator Prize Awarded to Dr. Timothy Niewold Timothy B. Niewold, MD, Mayo Clinic rheumatologist and associate professor of medicine at the Mayo Clinic College of Medicine, Rochester, Minn., was awarded the 2015 Mary Betty Stevens Young Investigator Prize at a reception held during the 2015 ACR/ARHP Annual Meeting in San…

    Familial Patterns in Childhood- & Adult-Onset SLE

    October 12, 2020

    A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences